On June 27, the U.S. Food and Drug Administration (FDA) announced approval of daratumumab (Darzalex®) in combination with lenalidomide and dexamethasone (Rd) for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).
Read FDA announcement.
From challenging misconceptions about breast cancer to incorporating paramedical tattooing for survivors after reconstruction, gather valuable takeaways from Oncology Issues in observance of Breast Cancer Awareness Month.
